Xilio Therapeutics GAAP EPS of -$0.90

Aug. 09, 2022 8:37 AM ETXilio Therapeutics, Inc. (XLO)By: Gaurav Batavia, SA News Editor
  • Xilio Therapeutics press release (NASDAQ:XLO): Q2 GAAP EPS of -$0.90.
  • $159.4 million in cash and cash equivalents as of June 30, 2022 expected to provide cash runway into first half of 2024; multiple data milestones anticipated for XTX101 and XTX202 in 2023

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.